Clinical Trial Update: EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx

View source ↗

Summary

Marketing approval has been granted for Lutathera (lutetium-177 dotatate) for somatostatin receptor‑positive neuroendocrine tumors, including patients with prog…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

Sponsor: Advanced Accelerator Applications | Conditions: Neuroendocrine Tumors | Status: APPROVED_FOR_MARKETING